Can low sex hormone signaling amplify fatigue and body-composition changes?

The transition to low sex hormone signaling, such as postmenopausal estrogen decline, initiates a systemic cascade that alters cellular bioenergetics, endocrine feedback loops, and inflammatory pathways.

Mechanistic pathways and fatigue

• Mitochondrial dysfunction: Declining estrogen impairs mitochondrial biogenesis and complex IV activity, directly reducing ATP production efficiency and compromising physical and cognitive energy.
• Endocrine and inflammatory feedback loops: HPA-axis hypofunction, characterized by blunted diurnal cortisol variation, diminishes the body's natural anti-inflammatory restraint. This allows systemic cytokines like TNF-alpha and IL-6 to rise unchecked.
• Energy vulnerability: High reactive oxygen species (ROS) and mitochondrial distress activate the NLRP3 inflammasome. These pro-inflammatory cytokines then directly suppress mitochondrial ATP generation, establishing a self-reinforcing cycle of cellular energy depletion and profound fatigue.

Drivers of body-composition changes

• Adipose tissue remodeling: Estrogen deficiency shifts adipose tissue macrophages toward a pro-inflammatory M1 phenotype, impairing fatty acid oxidation and driving visceral adiposity.
• Muscle tissue degradation: Reduced sex hormone signaling accelerates sarcopenia by impairing mitophagy, disrupting mitochondrial dynamics, and triggering myofiber apoptosis.
• Thyroid-axis interaction: Concomitant thyroid-axis strain, such as hypothyroidism, further alters skeletal muscle substrate utilization, compounding muscle atrophy and slower contraction kinetics.

Bottom line

• Low estrogenic and androgenic signaling acts as an upstream trigger, interacting with HPA-axis hypofunction, thyroid strain, mitochondrial vulnerability, and chronic inflammation to drive a multi-system cycle of persistent fatigue, visceral fat accumulation, and skeletal muscle decline.